Type 1 Diabetes, Type 2 Diabetes
Conditions
Keywords
Diabetes, Type 1 Diabetes, Type 2 Diabetes, Physiologic Insulin, Basal Insulin, Bolus Insulin, Mealtime insulin, Insulin patch, Multiple daily injections
Brief summary
The primary objective of this study is to compare patient preference of the h-Patch as delivery device for insulin lispro compared with either an insulin pen or needle and syringe in patients with diabetes, either Type 1 or Type 2, on stable multiple daily injection regimens. This will be assessed using an accepted preference scale.
Detailed description
Patients with Type 1 Diabetes have an absolute deficiency in insulin production and benefit from physiologic insulin replacement, defined as administration of background and mealtime insulin. More than half of patients with Type 2 diabetes (T2DM) have less than 50% of their beta cell function at the time of diagnosis. Because of this, these patients would also benefit from the physiologic delivery of insulin. Currently, 4 or more injections per day are required to deliver the various different available insulins in a physiologic manner. Valeritas has developed the h-Patch, a device suitable to make the delivery of basal and bolus insulin effective, simple and discrete. This study will measure patient preference, glucose control and safety of the h-Patch compared with patients' previous therapy. Patients previous therapy will be multiple daily injections delivered either by pens or needle and syringe.
Interventions
DEVICEh-Patch
Sponsors
Valeritas, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnosis of Type 1or Type 2 diabetes mellitus for at least a year 2. Stable insulin regimen for at least 3 months consisting of multiple daily injections of human regular or rapid acting insulin at meal times and long or intermediate acting insulin as basal. In this protocol multiple daily injections requires at least three injections daily. 3. Total daily insulin dose between 50 and 80 units. 4. If patient is Type 2, can be treated with metformin and/or a thiazolidinedione and/or a sulfonylurea, but other diabetes drugs including α-glucosidase inhibitors, meglitinides, pramlintide exenatide, and DPP-IV's are excluded. 5. HbA1c \> 7.0% and \< 9.0%.
Exclusion criteria
1. Recurrent major hypoglycemia or prolonged unstable blood glucose control (as judged by the Investigator). 2. Use of other diabetes drugs including α-glucosidase inhibitors, meglitinides, pramlintide, exenatide or DPP-IV inhibitors (metformin and/or a thiazolidinedione and/or a sulfonylurea are allowed). 3. Intend to use any other concomitant drug therapy (prescription or over-the-counter medications) that can affect blood glucose levels. 4. Have used systemic glucocorticoids within 1 month prior to Screening or currently on glucocorticoids. 5. Have a history of drug or alcohol abuse within 1 year prior to Screening Visit. 6. Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, or neurological disease that would, in the investigator's opinion, preclude safe participation in the study. 7. Have a history of major surgery, e.g. laparotomy, thoracotomy, open orthopedic procedure, etc. within 3 months prior to Screening Visit. 8. Evidence of significant neuropsychiatric disease. 9. Have participated in a medical, surgical, or pharmaceutical investigational new drug/device study in the last 30 days or ≤ 5 half-lives of the investigational drug, whichever is longer, prior to Screening Visit. 10. Blood donation of 500 ml or more in the last 2 months prior to Screening Visit. 11. Evidence of significant active hematological disease. 12. Acute infection with fever. 13. Hemoglobin \< 10 g/dL; AST, ALT ≥ 1.5 times the upper reference limit at Screening. 14. Uncontrolled treated/untreated hypertension (systolic blood pressure \> 155 mmHg and diastolic blood pressure \> 90 mmHg). 15. History of proliferative retinopathy or maculopathy requiring acute treatment 16. Mental incapacity, unwillingness or language barrier precluding adequate understanding or co-operation. 17. Any condition that the Investigator and/or Sponsor feel would interfere with trial participation or evaluation of results 18. Pregnancy, breast-feeding, intention of becoming pregnant for female patients of child-bearing potential. \-
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Mean glucose using CGM. | 4 weeks |
| Glucose SD, MAGE, Proportion of 24 hours in euglycemic range 70-160 mg/dl, using CGM. | 4 weeks |
| End of Study Patient Questions | 4 weeks |
| Hypoglycemia | 4 weeks |
| Proportion of time with glucose < 70 mg/dl, from CGM. | 4 weeks |
| Number and type of adverse events. | 4 weeks |
Countries
United States
Outcome results
None listed